Robert Michael Dudley - 28 Sep 2023 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role
Chief Executive Officer, Director
Signature
/s/ Thomas A. Fitzgerald, Attorney-in-Fact
Issuer symbol
RNAZ
Transactions as of
28 Sep 2023
Net transactions value
+$49,980
Form type
4
Filing time
02 Oct 2023, 16:37:49 UTC
Previous filing
22 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNAZ Common Stock Purchase $49,980 +98,000 +119% $0.5100 180,262 28 Sep 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired pursuant to an underwritten public offering of common stock by the Issuer.